Prime Vitality, Inc. dba Prime Peptides – FDA Warning Letter, Aug 3, 2026

On August 24, 2026, the FDA issued a warning letter to Royal Peptides LLC following a July 2026 review of the company’s website. The agency identified significant violations of the Federal Food, Drug, and Cosmetic Act, specifically regarding the sale of unapproved new drugs. The products in question include Tirzepatide, Semaglutide, Retatrutide, SS-31 (Elamipretide), PT-141, Tesamorelin, and BIMORELIN.

The FDA determined these products are drugs because they are marketed to treat or prevent diseases and influence body functions, such as promoting weight loss, improving metabolic health, and treating sexual dysfunction. Although Royal Peptides labeled the products "for research use only," the FDA found evidence of intended human use, including website resources like peptide calculators and guides for preparing injections. Because these injectable products have not undergone the required FDA approval process to verify their safety and effectiveness, their distribution in interstate commerce is illegal. The agency expressed particular concern regarding the safety of unapproved injectables, which bypass the body"s natural defenses and can cause life-threatening conditions.

Royal Peptides is required to investigate the root causes of these violations and implement corrective actions. The company must provide a written response to the FDA within 15 business days detailing the steps taken to address the issues and prevent their recurrence. Failure to comply may result in legal action, including product seizures or injunctions.